Additional details for the AACR presentations are as follows:
Presentation Date and Time: Monday, April 16, 2007, 8:00 AM -12:00 PM PT
Abstract #1894: Immune mechanisms of action of talabostat: a dipeptidyl peptidase targeted anti-tumor agent
Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM -12:00 PM PT
Abstract #5622: The anti-tumor potential of inhibitors of the DASH proteases in a mouse model of human breast cancer
The posters associated with the abstracts will be available on the Point Therapeutics' web site at www.pther.com immediately following their presentation.
About Point Therapeutics, Inc.:
Point is a Boston-based biopharmaceutical company currently studying its lead product candidate, talabostat, in two Phase 3 double blind, placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.
Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Director, Corporate Communications